US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Patency of the Ductus Arteriosus · Atopic Dermatitis · CNTB
S.L
S.L drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
SAN DIEGO, CA, EU HQ
Public company Type
CNTB · NYSE Ticker
Company details
- Status
- Public
- HQ
- SAN DIEGO, CA, EU
- Programs
- 15
- Drugs
- 11
- Patents
- 179
S.L pipeline
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
S.L drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
allogeneic umbilical cord-derived cd34- cells, non-expanded
Blood and blood forming organs (B05)Blood and blood forming organs (B05) compound in S.L's portfolio.
-
Development asset linked to S.L in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
Development asset linked to S.L in public FDA and regional records.
-
glycerol phenylbutyrate
Alimentary tract and metabolism (A16)US regulatory status: approved. Molecular target: Glutamine.
- Target
- Glutamine
- Mechanism
- Glutamine sequestering agent
-
Development asset linked to S.L in public FDA and regional records.
-
Development asset linked to S.L in public FDA and regional records.
-
Development asset linked to S.L in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to S.L in public FDA and regional records.